















  A NEW STABILITY INDICATING UPLC METHOD DEVELOPMENT AND VALIDATION FOR THE 
SIMULTANEOUS ESTIMATION OF METOLAZONE AND SPIRONOLACTONE IN BULK AND IN ITS
PHARMACEUTICAL FORMULATIONS
Y. ISMAIL1* K. B. CHANDRASEKHAR2 V. GUNASEKARAN3, ,
1JNIAS - JNTUA, Ananthapuramu, A. P. India, 2Director of Research and Development, Department of
Chemistry, JNTUA, Anantapuramu, A. P. India, 3Sri Venkateswara College of Pharmacy, Chittoor, A. P, India
Email: ismailpharmacy@yahoo.co.in
Received: 28 Aug 2014 Revised and Accepted: 30 Sep 2014
  
ABSTRACT 
Objective: The objective of the work is to develop and validate a new, simple, highly sensitive RP-UPLC method for simultaneous estimation of 
Metolazone and Spironolactone in bulk and in its dosage forms.  
Methods: The method was developed on a reversed-phase Hypersil Gold C18 
Results: The results were obtained as follows- the retention times were found to be around 2.888 min and 3.835 min, the percentage purity was 
observed to be 99 % w/v and 100 % w/v, the percentage recovery was found to be 99.90% and 99.9% respectively for Metolazone and 
Spironolactone. Calibration plots were linear (r
(2.1× 100 mm, 2.7 µm) column with isocratic elution. Detection was 
done by UV-Spectroscopy at a detection wavelength of 235 nm. The analytical procedure was validated by assessing the specificity, linearity, 
precision, accuracy, limit of detection, limit of quantification, robustness and ruggedness as per ICH guidelines. 
2
Conclusion: The developed analytical 
 > 0.999) over the concentration range of 12 to 28μg/ml for Metolazolone and 120 to 280μg/ml for 
Spironolactone. The LOD was 0.0002µg/ml for Metolazone and 0.01µg/ml for Spironolactone. The LOQ was found to be 0.0008µg/ml for 
Metolazone and 0.003µg/ml for Spironolactone.  
method for the simultaneous quantitation of Metolazone and Spironolactone was found to be specific, rapid, 
reliable, and reproducible. No interference from any component of pharmaceutical dosage form was observed. The method
Keywords: RP-UPLC, ICH, Metolazone, Spironolactone, UV-Spectroscopy, LOD, LOQ. 
 is amenable to the 
routine analysis of large numbers of samples with good precision and accuracy. 
 
INTRODUCTION 
It was the Russian botanist Mikhail Tsvet (Mikhail Semyonovich 
Tsvet, 1872-1919) [1] who invented the first chromatography 
technique in 1901 during his research on chlorophyll. He used a 
liquid-adsorption column containing calcium carbonate to separate 
plant pigments. The method was described on December 30, 1901 at 
the XI Congress of Naturalists and Doctors in St. Petersburg. 
Chromatography is derived from Greek words “chroma” means 
“color” and “graphing” means “writing” in English [2,3].  
UPLC system was designed to provide highest analysis speed and 
resolution and at the same time keep system pressure at a minimum. 
UPLC is up to 20 times faster than HPLC with same or better 
performance, 60% higher resolution, 10% more sensitive, Peak 
capacity is 1.4 % more, Reduced runtime from 60 to 20 min (related 
substances) and cut cost by 60%[4] thus this is the fastest, most 
efficient and cost effective LC system compared to HPLC.  
Metolazone (MET) [5], with the chemical name 7-chloro-2-methyl-3-
(2-methylphenyl)-4-oxo- 1, 2, 3, 4-tetrahydroquinazoline-6-
sulfonamide (Fig.1) is a quinazoline diuretic, which is widely used in 
the treatment of hypertension. A proximal action of metolazone has 
been shown in humans by increased excretion of phosphate and 
magnesium ions and by a markedly increased fractional excretion of 
sodium in patients with severely compromised glomerular filtration.  
Spironolactone (SPI)[6,7,8], with the chemical name 17-hydroxy-7α 
- mercapto-3-oxo-17α -pregn-4-ene-21-carboxylic acid γ-lactone 
acetate (Fig.2) is a renal competitive aldosterone antagonist in a 
class of pharmaceuticals called potassium-sparing diuretics. It 
causes increased amounts of sodium and water to be excreted, while 
potassium is retained. Spironolactone acts both as a diuretic and as 
an antihypertensive drug by this mechanism. It may be given alone 
or with other diuretic agents which act more proximally in the renal 
tubule. Aldosterone interacts with a cytoplasmic mineralocorticoid 
receptor to enhance the expression of the Na+, K+-ATPase and the 
Na+ channel involved in a Na+ K+ transport in the distal tubule. 
Spironolactone bind to this mineralocorticoid receptor, blocking the 
actions of aldosterone on gene expression. Aldosterone is a hormone; 
its primary function is to retain sodium and excrete potassium in the 
kidneys. Literature survey [9,10,11,12] revealed that no stability 
indicating UPLC method for simultaneous estimation of Metolazone and 
Spironolactone was reported. Hence the objective was to develop a 
stability indicating, simple, sensitive, accurate and precise method for 
Simultaneous Determination of Metolazone and Spironolactone in bulk 
and in its Pharmaceutical Dosage form by UPLC. 
 
 
Fig. 1: Chemical Structure of Metolazone. 
 
 
Fig. 2: Chemical Structure of Spironolactone. 
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MATERIALS AND METHODS 
Chemicals and reagents 
Pure samples of Metolazone and Spironolactone were obtained from The 
Madras Pharmaceuticals, Chennai. The commercial samples of the 
tablets Metolactone containing Metolazone-5mg and Spironolactone-
50mg were provided by CENTAUR Pharmaceuticals Pvt. .Ltd. HPLC 
grade Acetonitrile and Methanol were procured from Merck Ltd. 
(Mumbai, India.). Water (HPLC) was obtained from a Milli-QRO water 
purification system. All the other used reagents were of analytical grade. 
Chromatographic Conditions 
Chromatographic separation was achieved by using a Waters e2695 
Separation Module UPLC system and a UV-visible detector. The 
chromatographic column utilized in the study was Hypersil Gold 
C18
10 μl of standard and sample solutions were injected into the 
injector of UPLC, and the peak dareas of the drugs in standard and 
sample were compared and assay was performed. Metolazone and 
Spironolactone shows the percentage purity values of 99 % w/v and 
100 % w/v respectively.  
RESULTS AND DISCUSSION 
Specificity 
The specificity of the method was confirmed by injecting the placebo 
and placebo spiked standard and observed that there was no shift in 
wavelength interference due to placebo. This confirms the specificity 
of the proposed method. There is no peak in the blank and Placebo 
solution run at the retention time corresponding to Metolazone and 
Spironolactone as in standard run as shown in (Fig.3). 
 
(2.1× 100 mm, 2.7 µm). Different mobile phases were tried, and 
the one containing Methanol, Acetonitrile and Phosphate Buffer (pH 
3.5 adjusted with Orthophosphoric acid) in the ratio of 50:32:18 v/v 
was considered to be appropriate.  
The mobile phase was filtered through 0.45μm membrane filter and 
ultra sonicated for 10 minutes. The flow rate selected was 1.0 
ml/min with wave length of 235 nm. All the determinations were 
performed at constant column temperature (Ambient) and an 
injector volume is 10μl. The spectra were obtained from the UV 
detector.  
Preparation of standard solution metolazone & spironolactone 
Accurately 5 mg Metolazone and 50 mg spironolactone were 
weighed and transferred into 50 ml volumetric flask, about 15 ml of 
diluent was added and sonicated for 30 minutes to dissolve it. The 
volume was made up with diluent. 
From this 5 ml of solution was pipetted out and transferred into 25 
ml of volumetric flask and the volume was made up with diluents 
and it gives the concentration of 20 µg/ml Metolazone and 200 
µg/ml spironolactone.  
Preparation of sample solution metolazone & spironolactone 
Metalactone tablets containing 5mg metolazone and 50mg 
spironolactone were weighed and the average weight was 
calculated. The tablets were powdered in a mortar and a sample of 
powder equivalent to 5mg metolazone and 50mg spiranolactone 
was transferred into a 50 ml volumetric flask and 15 ml of diluent 
was added, sonicated for 30 min and made up to the mark with 
diluents. Pipette out 5 ml of above solution into 25 ml volumetric 
flask and made up with diluents to obtain a concentration of 20 
µg/ml, 200 µg/ml of Metolazone and spironolactone respectively.  
Assay 
 
Fig. 3: chromatogram showing specificity of metolazone and 
spironolactone. 
 
Linearity and range 
Linearity was evaluated by visual inspection of plot of peak are as a 
function of analyte concentrations for Metolazone and 
Spironolactone. From the linearity studies the specified range was 
determined for Metolazone and Spironolactone given as 12 - 28 
μg/ml and 120-280 respectively. The results are reported in Table-
1. The calibration curves are shown in (Fig.4 & 5).  
 
Table 1: Linearity Results for Metolazone and Spironolactone 
Parameters  Metolazone Spironolactone 
Linear Dynamic Range 12-28μg/ml 120-280μg/ml 
Correlation Coefficient 0.999 0.999 
Slope (m) 23957 2335 
 
 
Fig. 4: Linearity of spironolactone 
 
Fig. 5: Linearity of metolazone 
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Table 2: system precision data for Metolazone 
 Sample Name Name R Area T Height  Tailing Plate Count 
 1 Sys pre MET 2.880 462743 76652 1.0 5874 
2 Sys pre MET 2.899 466576 76985 1.0 5833 
3 Sys pre MET 2.888 467653 77300 1.0 5967 
4 Sys pre MET 2.889 465737 76621 0.9 5834 
5 Sys pre MET 2.890 463971 76647 0.9 5870 
6 Sys pre MET 2.890 465863 76654 0.9 5798 
Mean    465960 76841   
Std. .Dev    1347 297   
%RSD    0.3 0.4   
 
Table 3: system precision data for Spironolactone 
 Sample Name Name R Area T Height Tailing Plate Count 
 1  Sys pre SPI 3.835 443864 59742 0.9 6716 
2 Sys pre  SPI 3.837 444847 58975 0.9 6713 
3 Sys pre  SPI 3.836 444064 59143 0.9 6742 
4 Sys pre  SPI 3.837 447868 58651 0.9 6583 
5 Sys pre  SPI 3.838 445701 58791 0.9 6763 
6 Sys pre  SPI 3.838 449686 58839 0.9 6673 
Mean    446433 58882   
Std. .Dev    2308 185   
%RSD    0.5 0.3   
 
Table 4: Method precision data for Metolazone 
S. No. Sample Name Name RT Area Height 
1 PRECISION MET 2.889 464597 76296 
2 PRECISION  MET 2.890 463482 76027 
3 PRECISION  MET 2.891 464533 75700 
4 PRECISION  MET 2.890 466393 75544 
5 PRECISION  MET 2.891 461733 75126 
6 PRECISION  MET 2.889 466272 75181 
Mean    464502 75646 
Std. Dev.    1756 462 
% RSD    0.4 0.6 
 
Table 5: Method precision data for Spironolactone 
S. No. Sample Name Name RT Area Height 
1 PRECISION  SPI 3.838 449484 58662 
2 PRECISION  SPI 3.839 448445 58434 
3 PRECISION  SPI 3.839 449133 58204 
4 PRECISION  SPI 3.839 446001 57950 
5 PRECISION  SPI 3.839 446901 57793 
6 PRECISION  SPI 3.838 447322 57659 
Mean    447881 58117 
Std. Dev.    1361 387 
% RSD    0.3 0.7 
 
Table 6: Results of Precision for Metolazone & Spironolactone: 
 S. No. Sample weight Sample area-1 Sample area-2 % Assay-1  % Assay-2  
 1 242 464597 449484 99 101 
 2 242 463482 448445 98 100 
 3 242 464533 449133 99 101 
 4 242 466393 446001 99 100 
 5 242 461733 446901 98 100 
 6 242 466272 447322 99 100 
Avg. assay    99 100 
 STD    0.37 0.30 
 % RSD    0.38 0.30 
 
Precision  
1) System precision 
The precision of the system was determined by six replicate injections of 
mixed standard solution. The % R. .S. .D of Area, retention time are 
present within the Acceptance criteria of 2 %. The results are reported in 
Table-2 & 3. The chromatograms are shown in (fig.6). 
2) Method Precision 
The precision of the method was determined by six replicate 
injections of sample solution. The % R. S. D of Area and retention 
time and assay are present within the acceptance criteria of 2 %.  
The results are reported in Table- 4, 5& 6. The chromatograms are 
shown in (fig.7). 
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Fig. 6: Chromatogram showing system precision 
 
 
Fig. 7: Chromatogram showing method precision 
 
Thus the proposed method was found to be high degree of precision 
and reproducibility.  
D. System suitability 
System suitability parameters such as resolution, tailing factor, no. 
of theoretical plates were calculated and the results are presented in 
Table- 7. The chromatograms are shown in (fig-8). The resolution 
value of more than 2 indicates satisfactory results in quantitative 
work and the high resolution value obtained indicates the complete 
separation of the drugs. 
The tailing factor values for Metolazone and Spironolactone 
indicating the symmetrical nature of the peak. 
The no. of theoretical plates was high indicating the efficient 
performance of the column.  
 
Table 7: System suitability parameters of Metolazone & 
Spironolactone 
Parameters Metolazone Spironolactone 
Tailing factor 1.0 0.9 
Retention time 2.888 3.835 
Theoretical plates per unit 5907 6717 
 
E. Accuracy 
The validation of the proposed method was further verified by 
recovery studies. Acceptance criteria are 98 - 102 % w/v. The 
results are reported in Table - 8.  
 
Table 8: Accuracy data for Metolazone and Spironolactone 
Parameters Metolazone Spironolactone 
% recovery 
50 % 99.6 99.7 
100 % 99.8 99.7 
150 % 99.8 99.9 
 
Fig. 8: chromatogram showing system suitability of metolazone 
and spironolactone. 
 
This serves as a good index of the accuracy and reproducibility of 
the proposed method. 
F. Robustness  
Robustness was determined by carrying out the assay during which 
flow rate and temperature were altered slightly. The results are 
reported in Table- 9.  
 
Table 9: Robustness data for Metolazone and Spironolactone 
Parameters % RSD Metolazone % RSD Spironolactone 
Flow rate 0.2 0.3 
Temperature  0.4 0.3 
% RSD values for robustness indicated that the method is robust and 
does not show variations in the results on slight variations in flow 
rate and temperature. 
 
G. Ruggedness 
Ruggedness was determined by carrying out the assay during under 
a variety of conditions, such as different laboratories, analysts, 
instruments, environmental conditions, operators and materials. 
There was reproducibility of test results under normal, expected 
operational conditions from laboratory and from analyst to analyst. 
The results are reported in Table - 10.  
The method is rugged and does not show variations in the results on 
slight variations of parameters. 
 
Table 10: Ruggedness data for Metolazone and Spironolactone 
 Parameters % RSD Metolazone % RSD Spironolactone 
Analyst 1 0.004 0.0003 
Analyst 2  0.002 0.001 
% RSD values for ruggedness indicated that the method is rugged 
and does not show variations in the results when performed by 
different analysts. 
 
Limit of detection  
The limit of detection of Metolazone and Spironolactone were calculated 
and found to be 0.0002 µg/ml and 0.011 µg/ml respectively.  
Limit of quantification  
The limit of quantification of Metolazone and Spironolactone were 
calculated and found to be 0.0008 µg/ml and 0.003 µg/ml 
respectively. 
Degradation studies degradation studies 
Degradation studies were carried out as per ICH guidelines. The 
sample solutions were subjected to acidic, basic, peroxide, water and 
light. Where as in acidic, basic the % degradations were found to be -
7 %, -8 % and -9 %, -9 % for Metolazone and spironolactone 
respectively. The % degradation by peroxide was found to be -6 % 
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and -5 %. The % degradation by water was found to be -8 % and -7 
%. The solid sample was subjected to light for 7 days and then the % 
degradation were found to be -5 % and -6 %. The results are 
reported in Table-11. 
 
Table 11: Results of degradation studies for metolazone and spiranolactone 
S. No. Name Sample weight Sample area-1 Sample area-2 % Assay-1 % Assay-2 % DEG-1 % DEG-2 
1 Acid 242 464433 449828 92 92 -7 -8 
2 Base 242 463248 444682 90 91 -9 -9 
3 Peroxide 242 464134 445453 93 95 -6 -5 
4 Water 242 463892 444004 91 93 -8 -7 
5 Light 242 462924 446801 94 94 -5 -6 
 
CONCLUSION 
A new stability indicating analytical method is developed and 
validated for simultaneous estimation of Metolazone and 
Spironolactone by RP-UPLC technique. The sample preparation is 
simple, consumes less amount of mobile phase and the required 
time for analysis is very short, the information presented in the 
study could be very useful for the quality monitoring of metolazone 
and spironolactone in combined pharmaceutical dosage forms and 
can be used to check drug quality during stability testing. The 
analytical procedure is validated as per ICH guidelines and shown to 
be accurate, precise and specific. This method represents a fast 
analytical procedure for the simultaneous quantitation of 
Metolazone and Spironolactone. The method
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 is amenable for the 
routine analysis of large numbers of samples with good precision 
and accuracy. 
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